The reusable handpiece is now commercially available as part of the body contouring platform, which combines fat removal, electrosurgery, and Renuvion tissue contraction technology.
Apyx Medical initiated the full commercial launch of a reusable power liposuction handpiece for its AYON Body Contouring System in the third quarter of 2026, following positive feedback from key early adopter surgeons. The company announced the launch with its third quarter financial results.
The US Food and Drug Administration (FDA)-cleared the handpiece earlier this year. AYON is an all-in-one platform that combines fat removal, closed-loop contouring, electrosurgical capabilities, and Renuvion for tissue contraction.
“We are building on that foundation with the broader commercial launch of power liposuction, which has received very positive early feedback from surgeons since it received FDA clearance earlier this year. We estimate that approximately 70% of plastic surgeons use power liposuction, making this an important addition that broadens AYON’s appeal,” says Charlie Goodwin, president and CEO of Apyx Medical, in a release.
Third Quarter Results
Total revenue rose 9% to $14.0 million, compared with $12.9 million in the third quarter of 2025. Surgical Aesthetics revenue increased 17% to about $13.0 million, up from $11.1 million. The company attributes the gain to domestic AYON sales, which began with the system’s commercial launch in the third quarter of 2025, and to higher international sales of Renuvion generators. Domestic sales of standalone generators and global sales of single-use handpieces declined, partially offsetting those gains.
Revenue from the company’s original equipment manufacturer segment fell 42% to about $1.1 million, from $1.8 million, because of lower sales volume to existing customers, according to the company. Apyx Medical expects that segment’s revenue to decline for the year as it focuses on surgical aesthetics.
Other financial highlights for the quarter include:
- Gross profit increased 8% to $9.0 million, with gross margin steady at 64.2%, compared with 64.4% a year earlier.
- Operating expenses rose to $9.6 million from $9.1 million, driven by higher salaries and related costs and higher selling, general, and administrative expenses.
- Net loss attributable to stockholders narrowed to $1.8 million, or $0.04 per share, from $2.0 million, or $0.05 per share.
- Adjusted EBITDA was $0.4 million, compared with a loss of $0.1 million in the same period last year.
- Net cash used in operating activities was $1.6 million, compared with $3.5 million, and cash and cash equivalents totaled $25.8 million as of September 30.
Guidance and Clinical Data
Apyx Medical reaffirmed its full-year 2026 total revenue guidance of $59 million to $60 million, compared with $52.8 million in 2025. The company expects Surgical Aesthetics revenue of $54 million to $55 million, up from about $45.3 million in 2025, and original equipment manufacturer revenue of about $5.0 million, down from about $7.5 million. Gross margin is projected at 63% to 65%.
The company also lowered its operating expense outlook. It now expects $41 million to $42.5 million for the year, down from previous guidance of less than $45.0 million.
In clinical news, a prospective study published in Plastic and Reconstructive Surgery—Global Open examined Renuvion’s effects on biological markers associated with skin quality. Among six participants who completed six-month follow-up, treated tissue showed 30% greater elastin fiber density and 34% less inflammation than untreated control areas.
Photo caption: Apyx Medical has launched a reusable power liposuction handpiece for its AYON Body Contouring System (pictured).
File photo/Provided Apyx Medical
